Compare Sun Pharma with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs SANOFI INDIA - Comparison Results

SUN PHARMA     Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA SANOFI INDIA SUN PHARMA/
SANOFI INDIA
 
P/E (TTM) x 18.7 37.7 49.7% View Chart
P/BV x 2.0 6.7 29.7% View Chart
Dividend Yield % 0.8 1.3 61.8%  

Financials

 SUN PHARMA   SANOFI INDIA
EQUITY SHARE DATA
    SUN PHARMA
Mar-19
SANOFI INDIA
Dec-18
SUN PHARMA/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs6796,840 9.9%   
Low Rs3754,630 8.1%   
Sales per share (Unadj.) Rs121.11,203.1 10.1%  
Earnings per share (Unadj.) Rs13.4165.3 8.1%  
Cash flow per share (Unadj.) Rs20.7209.9 9.9%  
Dividends per share (Unadj.) Rs2.7584.00 3.3%  
Dividend yield (eoy) %0.51.5 35.6%  
Book value per share (Unadj.) Rs172.6963.6 17.9%  
Shares outstanding (eoy) m2,399.2623.03 10,418.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.44.8 91.3%   
Avg P/E ratio x39.434.7 113.6%  
P/CF ratio (eoy) x25.527.3 93.3%  
Price / Book Value ratio x3.16.0 51.3%  
Dividend payout %20.650.8 40.4%   
Avg Mkt Cap Rs m1,264,650132,078 957.5%   
No. of employees `00017.53.3 530.2%   
Total wages/salary Rs m59,6714,068 1,466.8%   
Avg. sales/employee Rs Th16,608.18,393.8 197.9%   
Avg. wages/employee Rs Th3,409.61,232.4 276.7%   
Avg. net profit/employee Rs Th1,833.81,153.0 159.0%   
INCOME DATA
Net Sales Rs m290,65927,708 1,049.0%  
Other income Rs m10,255897 1,143.2%   
Total revenues Rs m300,91428,605 1,052.0%   
Gross profit Rs m63,0766,235 1,011.6%  
Depreciation Rs m17,5331,027 1,707.2%   
Interest Rs m5,5537 79,321.4%   
Profit before tax Rs m50,2466,098 824.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-12,1440-   
Tax Rs m6,0092,292 262.2%   
Profit after tax Rs m32,0933,806 843.2%  
Gross profit margin %21.722.5 96.4%  
Effective tax rate %12.037.6 31.8%   
Net profit margin %11.013.7 80.4%  
BALANCE SHEET DATA
Current assets Rs m310,69215,922 1,951.3%   
Current liabilities Rs m173,3966,235 2,781.0%   
Net working cap to sales %47.235.0 135.1%  
Current ratio x1.82.6 70.2%  
Inventory Days Days9964 155.6%  
Debtors Days Days11221 534.7%  
Net fixed assets Rs m232,4777,539 3,083.7%   
Share capital Rs m2,399230 1,043.2%   
"Free" reserves Rs m411,69121,962 1,874.6%   
Net worth Rs m414,09122,192 1,865.9%   
Long term debt Rs m15,2260-   
Total assets Rs m646,93829,839 2,168.1%  
Interest coverage x10.0872.1 1.2%   
Debt to equity ratio x00-  
Sales to assets ratio x0.40.9 48.4%   
Return on assets %5.812.8 45.5%  
Return on equity %7.817.2 45.2%  
Return on capital %10.227.5 37.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m66,0257,587 870.2%   
Fx outflow Rs m38,6107,145 540.4%   
Net fx Rs m27,415442 6,202.5%   
CASH FLOW
From Operations Rs m21,9653,739 587.4%  
From Investments Rs m-6,813-731 931.9%  
From Financial Activity Rs m-27,305-1,972 1,384.6%  
Net Cashflow Rs m-8,4421,036 -814.8%  

Share Holding

Indian Promoters % 63.7 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 5.1 14.4 35.6%  
FIIs % 23.0 14.6 157.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 10.5 79.0%  
Shareholders   133,026 15,184 876.1%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   CADILA HEALTHCARE  TTK HEALTHCARE  ORCHID PHARMA LTD  BIOCON   J.B.CHEMICALS  

Compare SUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Crashes 1,203 Points; IT and Banking Stocks Witness Selling(Closing)

Indian share markets extended losses in the first trading session of FY21, as the number of coronavirus cases in the country continued to rise.

Related Views on News

SUN PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 29.8% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, SUN PHARMA has posted a net profit of Rs 10 bn (down 29.8% YoY). Sales on the other hand came in at Rs 82 bn (up 5.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SANOFI INDIA Announces Quarterly Results (1QFY20); Net Profit Down 2.2% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, SANOFI INDIA has posted a net profit of Rs 974 m (down 2.2% YoY). Sales on the other hand came in at Rs 7 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

More Views on News

Most Popular

Sorry Warren Buffett, I'm Following This Man Instead of You in 2020(The 5 Minute Wrapup)

Mar 30, 2020

This man warned of an impending market correction while everyone else was celebrating the renewed optimism in early 2020...

A Big Trading Opportunity is Coming Your Way Soon(Fast Profits Daily)

Mar 25, 2020

I see a big opportunity to make fast profits on the horizon.

The Biggest Trading Opportunity of 2020 is Here...

Mar 26, 2020

India's #1 trader, Vijay Bhambwani, talks about a hugely profitable trading opportunity which you must know about today!

Coronavirus Sell-off Is a Perfect Time to 'Lockdown' this 'Crorepati' Stock(Profit Hunter)

Mar 24, 2020

Coronavirus crisis and panic selling has brought this quality smallcap to multiyear lows, making it a great bargain.

Lockdown! Now the Bailout...(The Honest Truth)

Mar 25, 2020

Ajit Dayal on what India should do to manage the coronavirus impact on the economy.

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Apr 1, 2020 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE SUN PHARMA WITH

MARKET STATS